Current aspects of high-dose chemotherapy in germ-cell tumors.
The optimal treatment in patients with 'poor prognosis' germ-cell tumors (GCT) according to the 'International Germ Cell Cancer Collaborative Group' (IGCCCG)--classification and in patients with refractory or relapsed disease after cisplatin-based chemotherapy remains controversial. It is well known that the majority of these patients will suffer systemic relapses after primary or salvage treatment and most of them will ultimately die of their disease. Therefore, the optimizing of the standard treatment is clearly desirable. The question of using conventional-dose or high-dose chemotherapy (HDCT) in this high-risk patients is under discussion. However, HDCT as primary treatment in 'poor prognosis' patients and as first- or subsequent salvage therapy in patients with relapsed or refractory GCT remains to be a relevant curative option. Prognostic factors have recently been recognized to aid in this decision.
Rick
O
O
Medizinische Klinik II m.S. Onkologie/Hämatologie, Universitätsklinikum Charité, Campus Mitte, Humboldt Universität, Schumann Str. 20/21, 10117 Berlin, Germany.
Kollmannsberger
C
C
Beyer
J
J
Bokemeyer
C
C
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000628:therapy; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D016879:Salvage Therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents